Generics News--Pfizer and Ranbaxy Laboratories went to court last month over the industry's No. 1 pharmaceutical Lipitor. Ranbaxy is the first to challenge two of Pfizer's Lipitor patents, which are supposed to protect the statin from generic competition until at least 2009.
Ranbaxy's chances of prevailing in this case are slim, many analysts are saying, but the potential upside for Ranbaxy is tremendous. Lipitor generated $7.4 billion in U.S. sales for the 12 months ending September, according to IMS Health data.
COPYRIGHT 2004 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment